You are here

  • Home
  • Archive
  • Volume 69, Issue Suppl 2
  • P255 Once-daily Tiotropium Respimat® Add-on To At Least Ics Maintenance Therapy Reduces Exacerbation Risk In Patients With Uncontrolled Symptomatic Asthma

Article Text

Article menu

Download PDFPDF

Improving patient therapies in COPD
P255 Once-daily Tiotropium Respimat® Add-on To At Least Ics Maintenance Therapy Reduces Exacerbation Risk In Patients With Uncontrolled Symptomatic Asthma
Free
  1. DMG Halpin1,
  2. P Paggiaro2,
  3. E Bleecker3,
  4. M Engel4,
  5. P Moroni-Zentgraf4,
  6. H Schmidt4,
  7. HAM Kerstjens5
  1. 1Royal Devon and Exeter Hospital, Exeter, UK
  2. 2University of Pisa, Pisa, Italy
  3. 3Center for Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, USA
  4. 4Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an Der Riss, Germany
  5. 5University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Abstract

Background A reduction in asthma exacerbation risk may provide improvements in clinical burden, patient experience and healthcare costs. In Phase III trials, once-daily tiotropium (delivered via the Respimat® SoftMist™ inhaler) added on to at least inhaled corticosteroids (ICS) improved lung function in patients with symptomatic asthma. We investigated exacerbation risk in each trial.

Methods Five Phase III, double-blind, placebo-controlled, parallel-group trials in patients with symptomatic asthma. Patients received tiotropium Respimat® 5 µg or placebo as add-on to at least ICS maintenance therapy (Table). Pre-planned co-primary or secondary end points were time to first severe exacerbation and time to any asthma worsening.

Results Mean baseline% of predicted forced expiratory volume in 1 second, seven-question Asthma Control Questionnaire score and ICS dose (µg) were: 56.0 ± 13.1, 2.6 ± 0.7, 1198 ± 539 (PrimoTinA-asthma®); 75.1 ± 11.5, 2.2 ± 0.5, 660 ± 213 (MezzoTinA-asthma®); 77.7 ± 11.9, 2.1 ± 0.4, 381 ± 78 (GraziaTinA-asthma®). Tiotropium Respimat® 5 µg reduced severe asthma exacerbation risk by at least 21% in all three severity cohorts (Table) and asthma worsening risk versus placebo in all trials, with a statistically significant reduction in the PrimoTinA-asthma® trial.

Conclusion Once-daily tiotropium Respimat® 5 µg add-on to at least ICS maintenance therapy consistently reduced exacerbations across asthma severities and so may be a beneficial add-on option to reduce current and future exacerbation risk.

https://doi.org/10.1136/thoraxjnl-2014-206260.383

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.